Head to head
Apitegromab against Taldefgrobep alfa
Two myostatin-directed biologics that took different routes, one through spinal muscular atrophy and toward an FDA decision, the other into obesity as a standalone weight loss drug. The comparison is about what a myostatin blocker is for, which the field has not settled.
Column A
ApitegromabApitegromab (SRK-015)
An antibody against latent myostatin, under FDA review for spinal muscular atrophy (decision due September 30, 2026) and shown to preserve 55% of the lean mass otherwise lost on tirzepatide.
Column B
Taldefgrobep alfaTaldefgrobep alfa (BHV-2000)
Biohaven's anti-myostatin/activin fusion protein being tested as a standalone weight-loss drug, with a Phase 2 obesity readout expected in the second half of 2026.
Side by side, on the facts we can check
| Attribute | Apitegromab | Taldefgrobep alfa |
|---|---|---|
| Category | Muscle & Performance | Muscle & Performance |
| FDA status | Under FDA review for SMA (PDUFA September 30, 2026); investigational in obesity | Investigational; Phase 2 |
| Half-life | Not established (antibody; monthly intravenous dosing) | Weekly or monthly subcutaneous dosing |
| Molecular weight | 144,734 Da (IgG1 monoclonal antibody) | 75,586 Da (adnectin-Fc fusion protein) |
| Mechanism | Monoclonal antibody that binds pro/latent myostatin and prevents its activation, increasing skeletal muscle mass. | Fusion protein that neutralizes myostatin and inhibits activin receptor type II signaling. |
| Human studies cited | 2 | 2 |
| Legal status, US | Investigational, not approved | Investigational, not approved |
Frequently asked questions
What is the difference between Apitegromab and Taldefgrobep alfa?
Apitegromab: An antibody against latent myostatin, under FDA review for spinal muscular atrophy (decision due September 30, 2026) and shown to preserve 55% of the lean mass otherwise lost on tirzepatide. Taldefgrobep alfa: Biohaven's anti-myostatin/activin fusion protein being tested as a standalone weight-loss drug, with a Phase 2 obesity readout expected in the second half of 2026.
Which has stronger research evidence, Apitegromab or Taldefgrobep alfa?
This database does not grade compounds. It counts what was run in people: 2 of the 2 studies cited on the Apitegromab profile were human work, against 2 of 2 for Taldefgrobep alfa. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Apitegromab and Taldefgrobep alfa FDA-approved?
Apitegromab: Under FDA review for SMA (PDUFA September 30, 2026); investigational in obesity. Taldefgrobep alfa: Investigational; Phase 2.
Related posts
Blog articles that cover Apitegromab or Taldefgrobep alfa, newest first.
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.